Work

OA02.05 First-In-Human Phase 1/2 Trial of Anti-AXL Antibody–Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC

Year: 2019

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.08.414

Authors: S. Ramalingam, J. Lopez, M. Mau-Sorensen, F. Thistlethwaite, S. Piha-Paul, S. Gadgeel, Y. Drew, P. Jänne, A. Mansfield, G. Chen, U. Forssmann, H. Johannsdottir, N. Pencheva, A. Ervin-Haynes, I. Vergote

Institutions: Emory University, Royal Marsden Hospital, Rigshospitalet, University of Manchester, The Christie NHS Foundation Trust, The University of Texas MD Anderson Cancer Center, University of Michigan, Dana-Farber Cancer Institute, Mayo Clinic, Genmab (Denmark), Genmab (Netherlands), Genmab (United States), Universitair Ziekenhuis Leuven

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2981446209

Cites:

Cited by: 20

Related to: 10